Adjuvant Treatment With Serplulimab Trastuzumab and SOX in the of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Serplulimab (Primary) ; Trastuzumab (Primary) ; Oxaliplatin; Tegafur
- Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Jun 2024 New trial record